Working towards personalization in medicine: Main obstacles to reaching this vision from today's perspective

Personalized Medicine

Volumn 11, Issue 7, 2014, Pages 641-649

  Leyens, Lada ^a   Horgan, Denis ^b   Lal, Jonathan A ^a   Steinhausen, Kirsten ^c   Satyamoorthy, Kapaettu ^d   Brand, Angela ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b European Alliance for Personalised Medicine   (Belgium)

^c FURTWANGEN UNIVERSITY   (Germany)

^d MANIPAL UNIVERSITY   (India)

Author keywords

cost benefit analysis; genomics; healthcare systems; P4 health; personalized medicine; public health genomics; stakeholder collaboration; systematic early dialog; technology transfer; translational research

Indexed keywords

ARTICLE; HEALTH CARE SYSTEM; HUMAN; MEDICAL RESEARCH; PERSONALIZED MEDICINE;

EID: 84909958544     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.55     Document Type: Article

References (33)

1. US FDA. Paving the Way for Personalised Medicine. FDA's Role in a New Era of Medical Product Development. US FDA, MD, USA (2013).
2. Castiglione F, Tieri PM, De Graaf A The onset of Type 2 diabetes: proposal for a multi-scale model. JMIR Res. Protoc. 2 (2), e44 (2013).
3. van Schalkwijk DB, De Graaf AA, Tsivtsivadze E Lipoprotein metabolism indicators improve cardiovascular risk prediction. PLoS ONE 9 (3), e92840 (2014).
4. Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin. Pharmacol. Ther. 95 (3), 281-293 (2014).
5. Ge D, Fellay JA, Thompson AJ Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (7262), 399-401 (2009).
6. Francioso S, Almerighi CP, Forte P A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial. Dig. Liver Dis. 46 (2), 164-169 (2014).
7. Pingle S, Sultana Z, Pastorino S In silico modeling predicts drug sensitivity of patient-derived cancer cells. J. Transl. Med. 12, 128 (2014).
8. Per Med. www.permed2020.eu.
9. Brand A. Public health genomics and personalized healthcare: a pipeline from cell to society. Drug Metab. Drug Interact. 27, 121-123 (2012).
10. Brand A, Lal JA. European best practice guidelines for quality assurance, provision and use of genome-based information technologies: the 2012 Decalaration of Rome. Drug Metabol. Drug Interact. 27 (3), 177-182 (2012).
11. EAPM. Innovation and Patient Access to Personalized Medicine. European Alliance for Personalised Medicine, Belgium (2013).
12. EAPM. Big Data Workshop. 16th European Health Forum Gastein. Gastein, Austria, 2-4 October 2013.
13. European Federation of Pharmacetical Industries and Associations. The Right Prevention and Treatment for the Right Patient at the Right Time. Outline Strategic Research Agenda for Abiomedical Research Public Private Partnership under Horizon 2020. European Federation of Pharmacetical Industries and Associations, Belgium (2013).
14. European Commission, Biobanks for Europe. A challenge for governance. 2012. http://bookshop.europa.eu/en/biobanks-for-europe-pbKINA25302/.
15. European Commission. Use of-Omics Technologies in the Development of Personalised Medicine. European Commission, Belgium (2013).
16. European Science Foundation, Forward Look, Personalized Medicine for the European Citizen. Towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM). 2012. www.esf.org/uploads/media/Personalised-Medicine.pdf.
17. eHealth Task Force. Redesigning Health in Europe for 2020. European Union, Luxembourg (2012).
18. F. Hoffmann-La Roche Ltd, Personalised Healthcare. Small difference, big effects. October 2011. www.roche.com/phc-brochure.pdf.
19. Federal Ministry of Education and Research(BMBF). Personalised Medicine-Action Plan, a new approach in research and health care. Germany. (2013).
20. European Hospital and Healthcare Federation (HOPE). Personalized Medicine in European Hospitals. PriceWaterhouseCoopers. London, UK (2011). www.efpia.eu/documents/92/61/BIG-DATA-Workshop-16th-European-Health-Forum-Gastein-Report.
21. iNNOVAHEALTH. Building on Open Innovation Ecosystem in Europe for Healthcare. Cyprus EU Presidency, Cyprus (2012).
22. Instituto Roche, La Medicina Individualizada como oportunidad para el Sistema Nacional de Salud. 2013. www.institutoroche.es.
23. l'Office parlementaire dvaluation des choix scientifiques et technologiques. Raport provisoire: les progrs de la gńtique, vers unemdecine de pŕcision ? les enjeux scientifiques technologiques, sociaux et thiques de la mdecine personnalis̈e. 22 January 2014. www.assemblee-nationale.fr/14/pdf/rap-off/i1724.pdf.
24. OPTI y Genoma Espaa, Farmacogeńmica: Medicina Personalizada y Predictiva. Informe de prospectiva Tecnoĺgica Sectorial. Genoma Espaa, April 2009. www.opti.org/publicaciones/pdf/texto123.pdf.
25. TAB, Individualisierte Medizin und Gesundheitssystem. Zukunftsreport. Bro fr Technikfolgen-Abschtzung beim Deutschen Bundestag, Germany (2008).
26. Technology Strategy Board. Stratified Medicine in the UK. Vision and Roadmap, UK (2011).
27. Roque F, Jensen PH, Schmock, Using electronic patient records to discover disease correlations and stratify patient cohorts. PLoS Comput. Biol. 7 (8), e1002141 (2011).
28. Lal J, Vaidya A, Gutierrez-Iberluzea I, Dauben HP, Brand A. The learning-adapting-leveling model: from theory to hypothesis of steps for implementation of basic genome-based evidence in personalized medicine. Pers. Med. 10 (7), 683-701 (2013).
29. Wason J, Marshall A, Dunn J, Stein RC, Stallard N. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. Br. J. Cancer 110 (8), 1950-1957 (2014).
30. Eichler HG, Oye K, Baird LG Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91 (3), 426-437 (2012).
31. Senior Medical Officer. Pilot Project on Adaptive Licensing. EMA, UK (2014).
32. Leopold C, Vogler S, Habl C, Mantel-Teeuwisse AK, Espin J. Personalised medicine as a challenge for public pricing and reimbursement authorities-a survey among 27 European countries on the example of trastuzumab. Health Policy 113 (3), 313-322 (2013).
33. Diseasome. www.diseasome.eu.